D. Anderson & Company Supports the American College of Rheumatology
D. Anderson & Company (DAC) will be a corporate sponsor of the American College of Rheumatology Research and Education Foundation. Established in 1985, the ACR Research and Education Foundation is the second-largest funding source for rheumatology research and training in the United States and aims to advance research and training to improve the health of people with rheumatic diseases.
"Having evolved from a niche contract research organization serving the rheumatology sector, DAC has been a longtime advocate of rheumatology education, research and practice support," said DAC President and CEO Diana Anderson, Ph.D. "We are proud to augment the work of the foundation and have made this our corporate cause for 2010."
Dr. Anderson is currently serving a second term on the ACR Research and Education Foundation Development Advisory Council, which is charged with providing oversight and leadership in raising philanthropic support. She is also a member of the Circle of Leadership-distinguished donors who contribute to the foundation's Annual Giving Campaign. Dr. Anderson is leveraging her industry influence to raise awareness and financial support of the foundation as it strives toward reaching a goal of $31 million over the next year.
Most notably, DAC is providing pro bono logistics and public relations services for the Dallas launch of the Within Our Reach campaign, the foundation's first and only disease-targeted research initiative. Since its launch in 2006, Within Our Reach has awarded 45 grants totaling $18 million toward innovative research focused on finding a cure for rheumatoid arthritis. The Dallas launch will get under way February 12 with an exclusive cocktail reception at the Rosewood Mansion on Turtle Creek in Dallas. Guests will include rheumatology doctors, patients and others seeking a cure for rheumatic diseases. Special guests include Stanley B. Cohen, M.D., president of the American College of Rheumatology.
"We are honored to have the support of Dr. Anderson and her team at D. Anderson & Company," Dr. Cohen said. "We have a long and storied history with DAC, given Dr. Anderson's leadership in the ACR Research and Education Foundation, and it seems a natural progression to partner with them on such an important project."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
